Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

3 1 1 1

What is this study about?

This clinical trial focuses on treating impetigo, which is a common bacterial skin infection that primarily affects children. The study compares two different forms of the same medication containing mupirocin – Impetine® Gel and Bactroban® Ointment – both applied directly to the skin to treat the infection.

The purpose of this research is to determine if using Impetine® Gel twice per day works as effectively as Bactroban® Ointment used three times per day in treating impetigo in children. Both medications contain the same amount of the active ingredient (20 mg/g of mupirocin), but they come in different forms – one as a gel and the other as an ointment.

The treatment period lasts for 7 days, during which participants will apply their assigned medication to the affected skin areas. The study will monitor how well the skin infection heals and check for any side effects. Doctors will examine the treated areas and evaluate the healing process using a special scoring system that looks at various signs of infection.

1 Initial visit and examination

A healthcare professional will examine the impetigo (skin infection) and take a sample from the affected area to confirm the presence of bacteria

The skin condition will be evaluated using a special scale called Skin Infection Rating Scale (SIRS)

For female patients of childbearing age, a urine pregnancy test will be performed

2 Treatment assignment

You will receive one of two treatments:

Either Impetine® Gel (mupirocin 20 mg/g) to be applied twice daily

Or Bactroban® Ointment (mupirocin 20 mg/g) to be applied three times daily

Both medications are applied directly to the skin

3 Treatment period and end of treatment visit

You will apply the assigned medication as directed

At the end of treatment visit (EOT), a healthcare professional will examine your skin

The SIRS evaluation will be performed to assess your progress

You will be asked about your satisfaction with the treatment

Any side effects will be recorded

4 Final follow-up visit

At the end of follow-up visit (EOF), your skin will be examined one final time

The SIRS evaluation will be performed to determine if the infection is cured

A sample from the affected area may be taken to check if the bacteria are gone

Any final side effects will be recorded

Who Can Join the Study?

  • Must have a clinical diagnosis of bullous or non-bullous impetigo (a bacterial skin infection)
  • Must be in good overall health, without any significant medical conditions other than impetigo that could affect study evaluations
  • The impetigo condition must be suitable for treatment with a topical antibiotic alone (medicine applied to the skin)
  • Must be between 18 months and 15 years old when joining the study
  • Must have a positive test result for specific bacteria (Staphylococcus aureus and/or Streptococcus pyogenes) from the infected skin area
  • Must have a minimum score of 4 on the Skin Infection Rating Scale (SIRS) with at least 3 different signs or symptoms present
  • Skin type must allow proper evaluation of infection symptoms
  • Must have parent or legal guardian consent, and children 12 years or older must also provide their own agreement
  • Participant and parents/guardians must be able to understand and follow study requirements
  • For participants who can become pregnant:
    • Must have a negative pregnancy test at the start of the study
    • Must agree to use appropriate birth control if sexually active

Who Cannot Join the Study?

  • History of allergic reactions to mupirocin (the active ingredient in study medications) or similar antibiotics
  • Currently taking other antibiotics (oral or topical) for skin infections
  • Severe or extensive skin infections requiring oral or intravenous antibiotics
  • Skin conditions that could interfere with evaluating the treatment response, such as eczema (inflamed, itchy skin) or psoriasis (scaly patches on skin)
  • Weakened immune system due to medical conditions or medications
  • Pregnancy or breastfeeding
  • Active skin cancer or history of skin cancer in the affected areas
  • Treatment with any investigational drug within 30 days before study entry
  • Inability to follow study procedures or attend follow-up visits
  • Known kidney or liver problems that could affect drug metabolism
  • Current participation in other clinical trials
  • History of poor compliance with medical treatments

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
CAP Oliveros Almeria Spain
CAP Sanchinarro Madrid Spain
CAP Gregorio Marañón Alcorcon Spain
CAP Alhambra L'hospitalet De Llobregat Spain
CAP Doctor Luengo Rodríguez Mostoles Spain
CAP Parque Loranca Fuenlabrada Spain
CAP Valdelasfuentes Alcobendas Spain
CAP Alicante Fuenlabrada Spain
CAP Las Américas Parla Spain

Other Sites

Site Name City Country Status
Servei De Salut De Les Illes Balears Palma Spain
Cqo Caz Bmx Barcelona Spain
Caa Lr Mkfw Sant Adria del Besos Barcelona Spain
Cum Pxsyqdw Madrid Spain
Cmm Lmh Tjmovz Madrid Spain
Cxv Npkls Anjyfczbu Almeria Spain
Cvg Sdipe Rijw Cordoba Spain
Cy Hrsvfe dz lqn Fzojvve Leganes Spain
Chp Lqc Pgxejdet Parla Spain
Cos Lumb Vwpuf Alcala De Henares Spain
Cmj Plpkmk Olkje Alcorcon Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Recruiting
09.06.2025

Trial locations

Impetine® Gel (mupirocin) is a topical antibiotic medication in gel form that is applied directly to the skin to treat impetigo, which is a bacterial skin infection. The gel formulation is designed to be easy to apply and is being tested with twice-daily application.

Bactroban® (mupirocin) is a topical antibiotic ointment that is also used to treat impetigo. It is the established treatment option and is typically applied three times per day. The ointment formulation has been widely used as a standard treatment for bacterial skin infections.

Both medications contain the same active ingredient (mupirocin) but come in different forms (gel versus ointment) and are being tested with different application schedules to determine if the gel version can be equally effective with fewer daily applications.

Impetigo – A highly contagious bacterial skin infection that primarily affects children but can occur at any age. The condition typically begins as small red sores that quickly turn into fluid-filled blisters, which eventually burst and develop honey-colored crusts. These sores most commonly appear around the nose and mouth but can spread to other parts of the body through skin-to-skin contact or by touching contaminated objects. The infection occurs when bacteria enter through breaks in the skin, such as cuts, scrapes, or insect bites. Impetigo usually starts in a small area and can spread to other areas of the body through scratching or touching.

Trial ID:
2024-517475-20-00
Protocol code:
OP-IPTC02
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Adjuvant mRNA-4157 and pembrolizumab for patients with completely resected high‑risk stage I non‑small cell lung cancer

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Hungary Italy The Netherlands +2
  • Study on the Effectiveness and Safety of Nemtabrutinib for Patients with Blood Cancers, Including CLL, SLL, MCL, MZL, FL, and Waldenström’s Macroglobulinemia

    Recruiting

    2 1 1 1
    Investigated diseases:
    Czechia Denmark France Germany Hungary Ireland +4